The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs. 

However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.

Hear about new innovative containment risk assessment tools and containment strategies when handling HPAPI products. Guidance for the evaluation and management of cross-contamination will be addressed, as well as newest control strategies and solutions.
Pharmaceutical companies will be presenting their approaches to scale-up processes and will be discussing manufacturing facility designs and requirements, also introducing flexible facilities. Learn more about CMO selection strategies and how to improve information and technology transfer.

This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find innovative new solutions.